Literature DB >> 23549634

Management of patients in a combined thyroid eye clinic in secondary care.

J D Benzimra1, A G Quinn, T Kersey, D McGrane, L Goss, B Vaidya.   

Abstract

The European Group on Graves' Orbitopathy (EUGOGO) recommends the use of specialised multidisciplinary clinics for the management of thyroid eye disease (TED). In the UK, many patients with TED are managed outside of specialised clinics. We describe the organisation of a combined TED clinic in a secondary care setting and present the result of a prospective audit of the patient characteristics and outcomes during the first four years of a combined TED clinic. Of a total of 132 patients referred to the TED clinic, 114 (86 %) had TED (90 females, median age 56 years; range 17-90 years). At presentation, 77 (67 %) were current or ex-smokers and 99 (87 %) were biochemically euthyroid. Median duration of eye symptoms was 12 months. Fifty-two percent, 45 and 3 had mild, moderate-to-severe and sight-threatening TED, respectively. Only 18 % of patients had a clinical activity score (CAS) of ≥3. Sixty-nine patients (61 %) required follow-up appointments in the TED clinic. In those who required follow-up, 43 % (n = 30) received either immunosuppressive or surgical treatment. CAS improved from first to final visit, with 29 % (n = 20) having a CAS of ≥3 at the first visit and 1 % (n = 1) at the final visit (p = 0.0001). There was also a decrease in prevalence of smoking and thyroid dysfunction at the final visit. A multidisciplinary specialised TED clinic offers an optimal setting for managing patients with TED; however, patients are often referred late to a specialist TED clinic.

Entities:  

Mesh:

Year:  2013        PMID: 23549634     DOI: 10.1007/s10792-013-9768-9

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  13 in total

1.  Multi-center study on the characteristics and treatment strategies of patients with Graves' orbitopathy: the first European Group on Graves' Orbitopathy experience.

Authors:  Mark F Prummel; Annemieke Bakker; Wilmar M Wiersinga; Lelio Baldeschi; Maarten P Mourits; Pat Kendall-Taylor; Petros Perros; Chris Neoh; A Jane Dickinson; John H Lazarus; Carol M Lane; Armin E Heufelder; George J Kahaly; Suzanne Pitz; Jacques Orgiazzi; Alain Hullo; Aldo Pinchera; Claudio Marcocci; Maria S Sartini; Roberto Rocchi; Marco Nardi; Gerry E Krassas; A Halkias
Journal:  Eur J Endocrinol       Date:  2003-05       Impact factor: 6.664

2.  Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO.

Authors:  Luigi Bartalena; Lelio Baldeschi; Alison Dickinson; Anja Eckstein; Pat Kendall-Taylor; Claudio Marcocci; Maarten Mourits; Petros Perros; Kostas Boboridis; Antonella Boschi; Nicola Currò; Chantal Daumerie; George J Kahaly; Gerasimos E Krassas; Carol M Lane; John H Lazarus; Michele Marinò; Marco Nardi; Christopher Neoh; Jacques Orgiazzi; Simon Pearce; Aldo Pinchera; Susanne Pitz; Mario Salvi; Paolo Sivelli; Matthias Stahl; Georg von Arx; Wilmar M Wiersinga
Journal:  Eur J Endocrinol       Date:  2008-03       Impact factor: 6.664

3.  Thyroid eye disease.

Authors:  Petros Perros; Christopher Neoh; Jane Dickinson
Journal:  BMJ       Date:  2009-03-06

4.  The Amsterdam Declaration on Graves' orbitopathy.

Authors:  Petros Perros; Wilmar M Wiersinga
Journal:  Thyroid       Date:  2010-03       Impact factor: 6.568

5.  Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy.

Authors:  M P Mourits; M F Prummel; W M Wiersinga; L Koornneef
Journal:  Clin Endocrinol (Oxf)       Date:  1997-07       Impact factor: 3.478

6.  Natural history of thyroid associated ophthalmopathy.

Authors:  P Perros; A L Crombie; P Kendall-Taylor
Journal:  Clin Endocrinol (Oxf)       Date:  1995-01       Impact factor: 3.478

7.  A questionnaire survey on the management of Graves' orbitopathy in Europe.

Authors:  P Perros; L Baldeschi; K Boboridis; A J Dickinson; A Hullo; G J Kahaly; P Kendall-Taylor; G E Krassas; C M Lane; J H Lazarus; C Marcocci; M Marino; M P Mourits; M Nardi; J Orgiazzi; A Pinchera; S Pitz; M F Prummel; W M Wiersinga
Journal:  Eur J Endocrinol       Date:  2006-08       Impact factor: 6.664

8.  The impact of thyroid eye disease upon patients' wellbeing: a qualitative analysis.

Authors:  Stephanie Estcourt; Bijay Vaidya; Anthony Quinn; Maggie Shepherd
Journal:  Clin Endocrinol (Oxf)       Date:  2007-10-31       Impact factor: 3.478

9.  Age and gender influence the severity of thyroid-associated ophthalmopathy: a study of 101 patients attending a combined thyroid-eye clinic.

Authors:  P Perros; A L Crombie; J N Matthews; P Kendall-Taylor
Journal:  Clin Endocrinol (Oxf)       Date:  1993-04       Impact factor: 3.478

10.  The patient experience of services for thyroid eye disease in the United Kingdom: results of a nationwide survey.

Authors:  Stephanie Estcourt; Janis Hickey; Petros Perros; Colin Dayan; Bijay Vaidya
Journal:  Eur J Endocrinol       Date:  2009-06-19       Impact factor: 6.664

View more
  3 in total

1.  Changing trend in referral to secondary care specialist thyroid eye disease clinic following the Amsterdam declaration.

Authors:  Annika S Quinn; Leticia R Dujardin; Bridget Knight; James Benzimra; Anthony G Quinn; Bijay Vaidya
Journal:  Int Ophthalmol       Date:  2017-02-08       Impact factor: 2.031

2.  Orbital decompression surgery for the treatment of Graves' ophthalmopathy: comparison of different techniques and long-term results.

Authors:  Mehmet Ozgur Cubuk; Onur Konuk; Mehmet Unal
Journal:  Int J Ophthalmol       Date:  2018-08-18       Impact factor: 1.779

3.  A 'Real Life' Service Evaluation Model for Multidisciplinary Thyroid Eye Services.

Authors:  Soma Farag; Claire Feeney; Vickie Lee; Sonali Nagendran; Rajni Jain; Ahmad Aziz; Rashmi Akishar; Vassiliki Bravis; Karim Meeran
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-07       Impact factor: 5.555

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.